PI
LRMR icon

PEAK6 Investments’s Larimar Therapeutics LRMR Stock Holding History

PEAK6 Investments’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$229K Hold
35,000
– – ﹤0.01% 2717
2024
Q2 		$254K Buy
35,000
+22,500
+180% +$172K ﹤0.01% 2635
2024
Q1 		$94.9K Sell
12,500
-17,500
-58% -$136K ﹤0.01% 3406
2023
Q4 		$137K Buy
+30,000
New +$101K ﹤0.01% 3433

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

PEAK6 Investments's LRMR Position: Q3 2024 in Review

PEAK6 Investments held its Larimar Therapeutics (LRMR) position steady in Q3 2024 at 35,000 shares worth $229K. The position accounts for ﹤0.01% of the portfolio, ranked #2717.

PEAK6 Investments first reported a position in LRMR in Q4 2023 and has held it in 4 quarters since. The position peaked at $254K in Q2 2024. 123 funds tracked by Wall St. Rank hold LRMR as of Q3 2024.

  • PEAK6 Investments held 35,000 shares of Larimar Therapeutics worth $229K as of Q3 2024.
  • PEAK6 Investments left its Larimar Therapeutics share count unchanged in Q3 2024.
  • Larimar Therapeutics made up ﹤0.01% of PEAK6 Investments's portfolio in Q3 2024, its #2717 holding.
  • PEAK6 Investments first reported a position in Larimar Therapeutics in Q4 2023 and has held it in 4 quarters since.
  • PEAK6 Investments's Larimar Therapeutics position peaked at $254K in Q2 2024.
  • 123 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q3 2024.

Based on PEAK6 Investments's 13F filing for Q3 2024, filed 14 Nov 2024.